The licence for Humira (adalimumab) in polyarticular juvenile idiopathic arthritis (pJIA) has been extended to include the treatment of children from 4 years-old. Humira can be given in combination with methotrexate when the response to one or more DMARDs is inadequate, or as monotherapy if methotrexate is inappropriate or not tolerated.
The recommended dose is 24mg/m2 (max 40mg) by subcutaneous injection every other week. To enable accurate dosing, Humira solution for injection is now available as a vial, in addition to the prefilled pen and syringe presentations.
Further Information: Abbott Laboratories Ltd
